Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
Investors were also not impressed with this committee's recommendation on RSV vaccines and believe that the target market for RSV vaccinations in the country has been narrowed. This new data, which was shared with the CDC's Advisory Committee on Immunization Practices (ACIP), showed that the vaccine efficacy of mResvia fell sharply in the second year, especially compared with rival vaccines marketed by GSK plc GSK and Pfizer PFE. An 18-month analysis of follow-up data showed that Moderna's RSV vaccine was just about 49.9% effective in preventing RSV-LRTD. This is significantly lower compared with the 80.9% vaccine efficacy achieved by the vaccine at a follow-up period of 3.7 months. This efficacy rate was also significantly lower compared with GSK's Arexvy and Pfizer's Abrysvo, both of which are also approved for similar use by the FDA. These companies also presented data on their respective RSV vaccines to the CDC's Advisory Committee on Immunization Practices (ACIP) Per GSK,
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Alexandria Real Estate Equities, Inc. Releases 2023 Corporate Responsibility Report Highlighting Its Longstanding Leadership at the Vanguard and Heart of the Life Science Industry [Yahoo! Finance]Yahoo! Finance
- Carisma jumps as drug discovery under Moderna deal leads to $2M payment [Seeking Alpha]Seeking Alpha
- Moderna RSV vaccine endorsed in EU [Seeking Alpha]Seeking Alpha
- Moderna, Inc. (NASDAQ: MRNA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- An Investigation Has Commenced on Behalf of Moderna, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your MRNA LossesAccesswire
MRNA
Earnings
- 5/2/24 - Beat
MRNA
Sec Filings
- 6/28/24 - Form 4
- 6/26/24 - Form 144
- 6/21/24 - Form 4
- MRNA's page on the SEC website